Review of clinical use of glucagon‐like peptide‐1 in the management of type 2 diabetes

This study confirms GLP‐1 agents provide clinically useful reductions in HbA1c and weight. Further work is required to assess their effect if used earlier. A practical and pragmatic approach to assessment of the effectiveness of GLP‐1 has been proposed. Copyright © 2014 John Wiley & Sons, Ltd.

Source: Practical Diabetes International - September 8, 2014 Category: Endocrinology Authors: Gordon F Rushworth, Jennifer Connelly, Wendy Laing, Benjamin H Maskrey, Fiona Nicholas, Sandra M MacRury Tags: Original Article Source Type: research